Compare iShares 10 20 Year Treasury Bond ETF (TLH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 10 20 Year Treasury Bond ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares 10 20 Year Treasury Bond ETF trades at $97.83, while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| TLH | VRTX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $105.36 | $529.59 |
52-Week Low | $97.13 | $366.54 |
Market Cap | — | $121.95B |
Enterprise Value | — | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLH trades at $98.13, down 0.56% today amid a bearish technical signal. The stock faces selling pressure with moving averages indicating a downtrend, while oscillators remain neutral. Recent dividends of $0.41 and $0.36 for H1-26 and H2-26 signal shareholder returns, but key valuation and profitability ratios are unavailable, limiting fundamental clarity.
The outlook is cautious due to bearish technicals and lack of financial metrics. Risks include market volatility from geopolitical tensions and Fed policy uncertainty. Investors need updated earnings and guidance to assess growth potential amid macroeconomic headwinds highlighted in recent financial news.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
